###### Strengths and limitations of this study

-   Prospective design from early pregnancy enables detailed and standardised collection of anthropometric measures and lifestyle questionnaires to give information on most known potential confounders to glycaemic regulation impairments.

-   Our biobank contains both maternal and fetal blood and placenta samples.

-   Participants are highly representative of the general population of pregnant women receiving obstetric care at our institution.

-   As our population is mostly Caucasian, results may not be entirely generalisable to more diverse populations.

Introduction {#s1}
============

Obesity and diabetes are major health problems recognised worldwide.[@R1] Excess adiposity is the main risk factor for insulin resistance (IR), type 2 diabetes (T2D) and gestational diabetes mellitus (GDM), all conditions that are associated with long-term cardiometabolic complications.[@R2] [@R3] The impact of impaired glucose regulation in pregnancy is especially worrisome because of associated short-term and long-term metabolic outcomes for both mothers[@R4] [@R5] and offspring.[@R6] Exposure to GDM during fetal development increases risk of macrosomia, fetal hyperinsulinaemia and neonatal hypoglycaemia at birth, in addition to IR, metabolic syndrome and T2D over the child\'s lifetime.[@R6] This long-term phenomenon is described as fetal programming.

The Genetics of Glucose regulation in Gestation and Growth (Gen3G) cohort aimed to increase our understanding of glucose regulation determinants in pregnancy and fetal growth with emphasis on interactions between genetics and environmental---or lifestyle---factors. We are especially interested in the roles of adipokines and vitamin D during pregnancy and in fetal development. By recruiting women at first trimester, we aimed to understand early pregnancy determinants implicated in the progressive gestational increase in IR and development of GDM. We are investigating genetic determinants of glucose regulation in pregnancy, so far based on hypothesis-driven candidate genes approaches, with the intent to use hypothesis-free approaches eventually. We are also interested in the consequences of maternal glycaemia and metabolic milieu alterations on epigenetic regulation in offspring energy and metabolic pathways.

Cohort description {#s2}
==================

Gen3G is a prospective observational cohort study. We recruited pregnant women representing the general population of women in reproductive age from the Eastern Townships region, in Québec, Canada.[@R9] The work conducted for the prospective follow-up during pregnancy and collection of samples and data presented here was funded by the Fonds de recherche du Québec---Santé, the Canadian Institutes of Health Research, the Canadian Diabetes Association (CDA), and Diabète Québec. Every participant gave written informed consent before enrolment in the study, in accordance with the Declaration of Helsinki.

We recruited a total of 1034 pregnant women between January 2010 and June 2013 (see [figure 1](#BMJOPEN2015010031F1){ref-type="fig"}). All women were invited to participate if they received prenatal care directly at or in a health centre affiliated with the CHUS and planned delivery at the CHUS. The CHUS is the only hospital in the Eastern Township region offering obstetric care for deliveries; it provides care for about 2800 deliveries per year. Nursing staff invited women to participate during a routine prenatal visit to the CHUS Blood sampling in pregnancy clinic,[@R9] all eligible women were invited with equal chance to participate in the study. If women were interested, research staff was contacted to describe the study and women could choose to contribute to different aims presented as substudies on adipokines, vitamin D and genetic determinants of gestational glucose regulation. Recruitment was eased because participation involved little additional burden to clinical requirements: drawing extra blood and answering questionnaires during visits that were clinically indicated at first and second trimesters, and collection of samples at delivery, all with minimal risk. If any woman was pregnant for a second time during the study timeline and wanted to participate again, the second index pregnancy was included separately and was identified with a distinct study identification number (31 women contributed 2 pregnancies during study).

![Flow chart illustrating the number of participants enrolled and active in the cohort from January 2010 to June 2013. GDM, gestational diabetes mellitus; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; OGTT, oral glucose tolerance test.](bmjopen2015010031f01){#BMJOPEN2015010031F1}

Compared with the general population of pregnant women receiving prenatal care and delivering at the CHUS, Gen3G participants showed similar demographic characteristics in terms of age, parity, pre-pregnancy body mass index (BMI) and ethnic background ([table 1](#BMJOPEN2015010031TB1){ref-type="table"}). Similar proportions of women with abnormal glucose tolerance were detected, and GDM screening was performed at the same time during second trimester. Based on this comparison, we feel confident that the cohort is representative of the population of pregnant women in our area.

###### 

Demographic characteristics of Gen3G participants and of the general population of pregnant women who delivered at the CHUS over same time period

                                                                                  Gen3G participants (n=1024\*)   CHUS patients, between 2008 and 2011 (n=7710)           
  ------------------------------------------------------------------------------- ------------------------------- ----------------------------------------------- ------- ---------------------
  Age (years)                                                                     1024                            28.0 \[25.0--31.0\]                             7507    28.0 \[24.0--31.0\]
  European descent                                                                1012                            964 (95.3)                                      5224    4758 (91.1)
  Primiparity                                                                     1024                            354 (34.6)                                      8579†   2849 (33.2)
  Self-reported pre-pregnancy BMI (kg/m^2^)                                       1014                            23.2 \[20.9--27.3\]                             7225    23.2 \[20.9--26.7\]
  Abnormal glucose tolerance at first trimester‡                                  1024                            9 (0.9)                                         3047    56 (1.8)
  GDM diagnosis at V2                                                                                                                                             5354    530 (9.9)§
   According to CDA¶                                                              823                             43 (5.2)                                                
   According to IADPSG                                                            823                             80 (8.9)                                                
  Gestational week at which GDM screening was performed in the second trimester   893                             26.2 \[25.6--27.1\]                             5361    26.4 \[26.0--28.0\]

2008 CDA criteria: 50 g glucose challenge followed by a 1 h plasma glucose. If 1 h plasma glucose \<7.8, no GDM. If 1 h plasma glucose ≥10.3, GDM diagnosis. If 1 h plasma glucose is 7.8--10.2, reassess with a 75 g OGTT (fasting plasma glucose \<5.3, 1 h plasma glucose \<10.6, 2 h plasma glucose \<8.9; if one value is exceeded, IGT diagnosis; if more than one value is exceeded, GDM diagnosis).

IADPSG criteria: 75 g OGTT with fasting, 1 and 2 h plasma glucose. If fasting plasma glucose ≥5.1 and/or 1 h plasma glucose ≥10.0 and/or 2 h plasma glucose ≥8.5, GDM is diagnosed.

\*In total,1034 participants accepted inclusion in the study, but multiple pregnancies (n=10) were excluded from these analyses.

†Total number of pregnancies, completed or not, seen at least once at the CHUS between 2008 and 2011.

‡Abnormal glucose tolerance was defined as reaching a blood glucose level ≥10.3 mmol/L 1 h after the 50 g GCT.

§Determined by the per cent of women referred to our institution\'s Endocrinology in Pregnancy Clinic; not all women performed 75 g OGTT or performed it at our institution.

¶Including GDM and IGT diagnoses as per the 2008 CDA guidelines for glucose levels above threshold at one time point (IGT diagnosis) or two time points (GDM diagnosis) during the 75 g OGTT (three points: fasting, 1 and 2 h).

BMI, body mass index; CDA, Canadian Diabetes Association; CHUS, Centre Hospitalier Universitaire de Sherbrooke; GDM, gestational diabetes mellitus; Gen3G, Genetics of Glucose regulation in Gestation and Growth; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

Study procedures {#s2a}
----------------

We collected data and samples at three time points during pregnancy (see [figure 1](#BMJOPEN2015010031F1){ref-type="fig"}). The first research visit (V1) was between 5 and 16 weeks of gestation, coinciding with women\'s first trimester prenatal clinical blood sampling as requested by their primary care physician. During this visit, we collected demographic data, medical history and anthropometric measurements; women completed questionnaires about lifestyle, and we collected extra blood samples during the clinically indicated blood draw (the majority during a 50 g glucose challenge test (GCT)). Most women performed this test as our cohort study happened in conjunction with a CDA-funded study (principal investigator: J-LA) investigating the value of a first trimester 50 g GCT in identifying women at risk of GDM later during pregnancy. Women were excluded (n=9) if they: had known pre-pregnancy diabetes, took medication that influenced glucose tolerance, had glycated haemoglobin (HbA1c) ≥6.5% or 1 h glucose ≥10.3 mmol/L post-50 g GCT, as this was classified as overt diabetes based on 2008 CDA criteria.[@R10] Maternal glycaemia was kept blinded if results of glucose levels after the 50 g GCT were \<10.3 mmol/L (per protocol of CDA-funded study).

The second visit (V2) was planned between 24 and 30 weeks, concomitantly with clinically indicated GDM screening test---in line with universal second trimester screening recommendations (both CDA and International Association of the Diabetes and Pregnancy Study Groups (IADPSG) guidelines).[@R10] [@R11] During V2, we updated medical history, repeated anthropometry measures, and women completed the same questionnaires about lifestyle. We collected extra blood samples at each point of the 75 g oral glucose tolerance test (OGTT; fasting, 1 and 2 h). Women diagnosed with GDM at that visit were followed up and treated according to 2008 CDA guidelines adopted at that time at our institution. Between V1 and V2, we excluded 81 (7.8%) women per protocol for miscarriage, medical abortions or health problems that prohibited participation (see [figure 1](#BMJOPEN2015010031F1){ref-type="fig"}). Another 45 (4.4%) participants moved away or declined further participation before V2.

At the end of pregnancy, we successfully collected clinical data from electronic hospital records for the majority of participants (82.9% of women recruited; 95.1% of women still active at V2). Information concerning 15 deliveries (1.7% of women still part of the study after V2) is missing or was excluded due to: delivery at another institution, active withdrawal or stillbirth. We collaborated with research in obstetric services (led by collaborator Dr J-C Pasquier) which offered trained research staff on call 24 h per day, 7 days per week and were directly contacted by clinical nurses from the obstetric department each time a study participant was admitted for delivery. These services were in place for multiple clinical research studies apart from Gen3G. Based on this unique set-up and in collaboration with researchers from the obstetric department, collection of biological samples for 736 (84.1%) deliveries was possible. Sample collection was missed for 147 deliveries (15.9%) for the following reasons: short time between participant admission and delivery, clinical staff omitted to contact research staff, communication issues (pager failure), coagulated cord blood before arrival of research staff, break in research staff services (holidays).

[Table 2](#BMJOPEN2015010031TB2){ref-type="table"} shows characteristics of women recruited in Gen3G that were followed until delivery compared with women who were excluded, withdrawn or lost to follow-up. No significant demographic differences between groups were observed. Familial history of diabetes was slightly more common in women who remained in the study. The proportion of women with positive personal history of previous GDM or macrosomic offspring was not different between women who completed the study and those who did not.

###### 

Demographic characteristics of women recruited in Gen3G that were followed until delivery compared with women who were excluded, withdrawn or lost to follow-up

  Characteristics                                                   Participants with delivery research data collected (n=854)   Participants lost to follow-up before or at delivery (n=170\*)   p Value
  ----------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------- ---------
  N (%) or median \[IQR\]                                                                                                                                                                         
  Age (years)                                                       28.0 \[25.0--31.0\]                                          28.0 \[25.0--31.0\]                                              0.46
  Primiparity                                                       294 (34.4)                                                   60 (35.3)                                                        0.45
  Self-reported pre-pregnancy BMI (kg/m^2^)                         23.3 \[20.9--27.3\]                                          22.7 \[20.9--27.5\]                                              0.49
  European descent                                                  814 (95.3)                                                   163 (90.6)                                                       0.11
  Positive family history of diabetes                               168 (19.7)                                                   22 (12.9)                                                        0.04
  Positive personal history of previous GDM or macrosomic newborn   89 (10.4)                                                    18 (10.6)                                                        0.95

p Value was determined with χ^2^ test for categorical data (parity, ethnicity, history of diabetes/GDM/macrosomic newborn) and Mann-Whitney test for continuous, non-parametric data (age, BMI).

\*Participants with multiple pregnancies, excluded shortly after inclusion per protocol, were not included in these analyses (n=10).

BMI, body mass index; GDM, gestational diabetes mellitus; Gen3G, Genetics of Glucose regulation in Gestation and Growth.

Data collection {#s2b}
---------------

### Maternal anthropometry and vital signs (V1, V2) {#s2b1}

Anthropometry was measured according to standardised procedures: weight (in kg) was measured with a calibrated electronic scale with bare feet in light clothing; height (in m) was measured with a wall stadiometer without shoes. BMI was calculated as weight divided by squared height (kg/m^2^). Body fat percentage (BFP) was estimated based on lean body mass measured by bioimpedance using a standing foot-to-foot scale (TBF-300A; Tanita. Coefficient of variation (CV): 2.1%[@R12]). Waist circumference (WC) was measured with a flexible measuring tape (in cm) above the top of the iliac crest; measurement was performed twice[@R13] and the average was recorded. Systolic and diastolic blood pressures were measured (in mm Hg) thrice in the sitting position after 5 min of rest; the average of these three measurements is used in analyses (see [table 3](#BMJOPEN2015010031TB3){ref-type="table"} for a general overview of characteristics in participants and offspring).

###### 

Gen3G participant\'s characteristics during pregnancy and at birth

  ----------------------------------------------------------------------------------------------------
  Parameter                                               Total valid n\*   Value
  ------------------------------------------------------- ----------------- --------------------------
  Baseline                                                                  

   Age (year)                                             962               28.4±4.5

   Ethnicity (% Caucasian)                                962               918 (95.4)

   Alcohol consumers (currently consuming)                962               10 (1.0)

   Alcohol consumption (portion per week)                 8                 0.7 \[0.2--7\]

   Smoking                                                962               

    Past smokers                                                            365 (37.9)

    Current smokers                                                         104 (10.8)

    Cigarettes smoked per day (in current smokers only)                     6.5 \[3.6--10.0\]

   Parity (% primiparous)                                 962               332 (34.5)

   Medical diagnosis                                      962               

    PCOS                                                                    16 (1.7)

    Asthma                                                                  63 (6.5)

    Allergies                                                               168 (17.5)

    Gastric reflux                                                          61 (6.3)

    Thyroid problems                                                        104 (10.8)

    Bladder problems                                                        20 (2.1)

    Mental health issues                                                    46 (4.8)

   Pre-pregnancy weight† (kg)                             952               63.5 \[56.8--74.8\]

   Pre-pregnancy BMI (kg/m^2^)                            952               23.3 \[20.9--27.4\]

  Visit 1                                                                   

   Gestational week                                       962               9.6±2.3

   Season of visit (% women recruited at)                 961               Summer:24%; Fall:23%\
                                                                            Winter:23%; Spring:30%

   Sun exposure†                                          943               

    High                                                                    645 (68.4)

    Medium                                                                  284 (30.1)

    Low                                                                     14 (1.5)

  Nutrition                                                                 

   Fruits and vegetables (times per day)                  777               5 \[4--7\]

   Breakfast consumption                                  947               

    Every day or most days                                                  886 (93.6)

    Less than most days                                                     61 (6.4)

   Restaurant meals (times per month)                     923               4 \[2--8\]

   Fish consumption (\>2 per week)                        955               150 (15.7)

  Physical activity                                                         

   Energy spent (kcal/kg/day)                             861               1.48 \[0.70--2.65\]

   Sleep duration (hours per night)                       861               8.3±1.3

   Sedentary activities (hours per week)                  857               15.7±8.8

  Anthropometry                                                             

   Weight (kg)                                            962               65.4 \[58.5--77.9\]

   BMI (kg/m^2^)                                          962               24.2 \[21.6--28.2\]

   Body fat (%)                                           957               32.0±8.5

   Waist circumference (cm)                               962               90 \[82.0--99.0\]

   Systolic/diastolic blood pressure (mm Hg)              960               110/69±10/7

  Blood biochemistry                                                        

   Glycaemic regulation                                                     

    Glycaemia post-50 g GCT (mmol/L)                      913               5.4 \[4.6--6.5\]

   Side effects due to the 50 g GCT (% yes)               962               288 (29.9)

    HbA1c (%)                                             956               5.2±0.3

   Apo B (mmol/L)                                         399               0.78±0.19

   Calcium (mmol/L)                                       960               2.23±0.10

   Phosphorus (mmol/L)                                    958               1.03±0.16

   Parathormone (pmol/L)                                  999               2.3 \[1.8--3.0\]

   Vitamin D \[25OHD~2~ and D~3~\] (nmol/L)               790               63.4±19.6

   Adiponectin (µg/mL)                                    479               11.8±4.6

   Peptide C (pg/mL)                                      814               1826 \[1436--2390\]

   Insulin (pg/mL)                                        814               1287 \[898--1817\]

   Leptin (pg/mL)                                         814               8467 \[4685--13 806\]

   TNFα (pg/mL)                                           814               1.58 \[1.20--2.12\]

  Visit 2                                                                   

   Gestational week                                       857               26.4±1.0

   Season of visit (% women with visit 2 at)              851               Summer:33%; Fall:24%\
                                                                            Winter:24%; Spring:19%

   Sun exposure†                                          847               

    High                                                                    550 (64.9)

    Medium                                                                  256 (30.2)

    Low                                                                     48 (5.7)

  Nutrition                                                                 

   Fruits and vegetables consumption (times per day)      824               6 \[5--8\]

   Breakfast consumption                                  843               

    Every day or most days                                                  829 (98.3)

    Less than most days                                                     21 (1.7)

   Restaurant meals (times per month)                     843               4 \[2--8\]

   Fish consumption (\>2 per week)                        850               131 (15.4)

   Physical activity                                                        

   Energy spent per day (kcal/kg)                         849               1.24 \[0.52--2.24\]

   Sleep duration (hours per night)                       839               8.1±1.4

   Sedentary activities (hours per week)                  834               17.1±10.1

  Anthropometry                                                             

   Weight (kg)                                            854               72.5 \[66.0--83.9\]

   BMI (kg/m^2^)                                          854               26.8 \[24.2--30.4\]

   Body fat (%)                                           846               35.9±6.7

   Systolic/diastolic blood pressure (mm Hg)              851               107/67±9/7

  Blood biochemistry                                                        

   Glycaemic regulation                                                     

    Fasting glycaemia (mmol/L)                            854               4.2 \[4.0--4.4\]

    Glycaemia 1 h into OGTT                               854               7.1 \[6.0--8.1\]

    Glycaemia 2 h into OGTT                               854               5.7 \[4.9--6.7\]

    Side effects due to the 75 g OGTT (% yes)             848               395 (46.6)

    HbA1c (%)                                             854               5.0 \[4.8--5.2\]

    GDM diagnosis                                         854               72‡ (8.4)

   Lipid profile                                                            

    Total cholesterol (mmol/L)                            853               6.20±1.11

    Triglycerides (mmol/L)                                853               1.92±0.63

    HDL cholesterol (mmol/L)                              824               1.92±0.42

    LDL cholesterol (mmol/L)                              818               3.46±1.00

    Apo A (mmol/L)                                        851               2.11±0.28

    Apo B (mmol/L)                                        851               1.21±0.28

    Fasting NEFA (nmol/L)                                 260               0.25±0.10

   Calcium (mmol/L)                                       835               2.08±0.12

   Phosphorus (mmol/L)                                    834               0.83±0.12

   Parathormone (pmol/L)                                  833               2.7 \[2.2--3.4\]

   Fasting adiponectin (µg/mL)                            843               12.5±4.7

   Fasting peptide C (pg/mL)                              820               844 \[630--1169\]

   Fasting insulin (pg/mL)                                795               293 \[213--412\]

   Fasting leptin (pg/mL)                                 824               14 093 \[8668--22 145\]

   Fasting TNFα (pg/mL)                                   825               1.62 \[1.18--2.19\]

  Delivery                                                                  

   Gestational week§                                      844               39.3±1.4

   End-of-pregnancy weight§¶                              841               78.2 \[71.3--90.0\]

   GDM treatment§                                         80                

    Not referred to CHUS GDM clinic                                         24 (30.0)

     Lifestyle                                                              19 (23.8)

    Lifestyle+pharmacological treatment                                     37 (46.3)

   Use of antibiotics before/during delivery§             807               301 (37.3)

   Anaesthesia (any kind)§                                813               742 (91.3)

   Delivery mode§                                         854               

    Caesarean section (first time)                                          77 (9.0)

    Caesarean section (iterative)                                           65 (7.6)

    Vaginal                                                                 712 (83.4)

  Newborns characteristics                                                  

   Sex (% female)§                                        854               410 (48.0)

   APGAR score at 1 min§                                  854               9 \[8--9\]

   APGAR score at 5 min§                                  854               9 \[9--10\]

   Breastfeeding status at discharge§                     739               

    Breastmilk only                                                         670 (90.7)

    Artificial only                                                         62 (8.4)

    Mixed                                                                   7 (0.9)

   Malformation§                                          853               12 (1.4)

   Admission to NICU§                                     805               81 (10.1)

   Hypoglycaemia at birth§                                807               94 (11.6)

   Hyperbilirubinaemia§                                   819               104 (12.7)

   Fracture or dislocation§                               806               9 (1.1)

  Anthropometry                                                             

   Birth weight (kg)§                                     851               3.405 \[3.115--3.705\]

   Birth weight z-score\*\*                               851               0.06±0.87

   Weight for gestational age\*\*                         851               

    Small                                                                   36 (4.2)

    Adequate                                                                752 (88.4)

    Large                                                                   63 (7.4)

   Body fat mass (kg)††                                   262               0.57±0.16

   Body fat percentage                                    262               16.5±3.1

   Birth length (cm)§                                     853               50.9±2.3

   Birth length z-score¶                                  846               0.32±0.82

   Head circumference (cm)§                               848               34.5±1.5

   Head circumference z-score\*\*                         848               0.04±0.95

  Cord blood biochemistry                                                   

   Vitamin D \[25OHD~2~ and D~3~\] (nmol/L)               655               52.8±18.2

   Adiponectin (µg/mL)                                    644               24.3±10.8

   Peptide C (pg/mL)                                      650               413 \[313--605\]

   Insulin (pg/mL)                                        655               315 \[236--431\]

   Leptin (pg/mL)                                         658               11 593 \[5842--19 494 \]

   TNFα (pg/mL)                                           660               5.37 \[4.13--6.86\]

   pH§                                                    830               7.24±0.22

   pCO~2~ (mm Hg)§                                        818               53.9 \[47.1--61.4\]

   pO~2~ (mm Hg)§                                         813               22.5 \[17.6--27.8\]

   HCO~3~ (mmol/L)§                                       818               23.3 \[21.5--25.0\]

   Haemoglobin (g/L)§                                     851               157 \[146--168\]

   Glucose (mmol/L)                                       660               4.44±0.93
  ----------------------------------------------------------------------------------------------------

\*This n indicates the maximum number of participants that contributed data for a specific variable at a specific time point.

†Self-reported.

‡Eight additional participants were diagnosed with GDM through other modes than IADPSG criteria before the research visit 2 and thus did not undergo a full OGTT.

§Starred variables were extracted from electronic hospital records.

¶Weight at the last routine visit before delivery, taken from the medical chart. The gestational week at which that measure was taken varies.

\*\*Fenton\'s chart[@R16] was used to calculate z-scores and weight for gestational age.

††Calculated from measured skinfold thickness (tricep, bicep, subscapulla and suprailiac folds).

Apo A, apolipoprotein A; Apo B, apolipoprotein B; BMI, body mass index; CHUS, Centre Hospitalier Universitaire de Sherbrooke; GDM, gestational diabetes mellitus; Gen3G, Genetics of Glucose regulation in Gestation and Growth; HbA1c, glycated haemoglobin; HCO~3~, bicarbonate concentration; HDL, high-density lipoprotein; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; LDL, low-density lipoprotein; NEFA, non-esterified fatty acids; NICU, neonatal intensive care unit; OGTT, oral glucose tolerance test; pCO~2~, partial pressure of carbon dioxide; PCOS, polycystic ovary syndrome; pH, acidity; pO~2~, partial pressure of oxygen; TNF, tumour necrosis factor.

### Neonatal anthropometry (delivery) {#s2b2}

Weight (in g) and length (in cm) of newborns were measured following standard clinical procedures, with an electronic scale and a measuring tape by obstetrics nurses within 2 h of delivery. We collected these and other relevant clinical information available in electronic medical records (detailed in [box 1](#bx1){ref-type="boxed-text"}). In January 2012, neonate skinfolds thickness (SFT) measurements were added to the protocol. We measured triceps, biceps, subscapular and suprailiac skinfolds (in mm) in duplicate on the right side of neonates. Trained research staff measured SFT following a standard procedure[@R14] with a calibrated skinfold caliper (AMG Medical). Triceps SFT was taken parallel to the long axis, midway between the acromial and the olecranon with the arm slightly flexed. Biceps SFT was measured at the middle point on the front of the slightly extended arm. Subscapular SFT was taken 1--2 cm below the lower tip of the scapula and suprailiac SFT was taken on the natural fold of the skin just above the iliac crest. Measures were recorded when the most constant reading was read on the caliper (considering neonate\'s movements). Triplicate measurement was taken if duplicate varied over 10.0%. We successfully measured SFT in a total of 265 newborns (31.0% of total deliveries, 67.3% of deliveries after initiation of SFT measurements in our research protocol). SFT are missing in cases where mothers did not give verbal consent following delivery, neonates were receiving care in the neonatology unit, or mothers and newborns were discharged home before trained research staff could measure SFT. Two trained research staff repeated SFT measures on the same 40 newborns (15.0%); interindividual variability was 1.5%. Box 1Data collected from staff-administered questionnaires and/or electronic medical data recordsV1 (n=1024)Date and season of visitAgeDate of last menses, planned delivery date, estimated gestational weekBlood groupAlcohol and tobacco use (never, prior and cessation date, or current and daily consumption)Medication in use at the time of the visit (including natural products, vitamin and mineral supplementation)Side effects of the glucose challenge test (when applicable)Parity (live births, stillbirths, abortions)Gestational diabetes mellitus (GDM) risk factors (according to Canadian Diabetes Association (CDA) and American Diabetes Association (ADA))Personal and familial medical historyMarital status, type of employmentHour of last food intake, hour of the day at which glucose challenge test was administeredSun exposure questionnaire (typical, trips, tanning)Diet (summary fish and milk consumption, weekly fruits and vegetables consumption, breakfast habits, restaurant visits)Physical activities: Commuting and daily living (including type of commuting, choice of stairs vs elevator) Last 3 months of leisure physical activities (derived from Canadian Community Health Survey (CCHS) questionnaire,[@R15] metabolic equivalent of tasks (METs) estimation) Daily sleep time Weekly work hours Weekly sedentary recreational activities time accorded to: computer, video game, television and readingV2 (n=854)Date and season of visitUpdated medication (including natural products, vitamin and mineral supplementation)Updated medical conditionsBlood group (confirmed)Oral glucose tolerance test\'s side effectsSun exposure (usual, trips, tanning)Summary fish and milk consumptionDiet (summary fish and milk consumption, weekly fruits and vegetables consumption, breakfast habits, restaurant visits)Physical activities: Commuting and daily living (including type of commuting, choice of stairs vs elevator) Last 3 months of leisure physical activities (derived from CCHS questionnaires[@R15], METs estimation) Daily sleep time Weekly work hours Weekly sedentary recreational activities time accorded to: computer, video game, television and readingDelivery: obstetric data abstracted from medical records (n=862)Gestational age at deliveryDiagnostics at delivery (GDM: type of treatment; other pregnancy complications)Labor details (spontaneous or induction, length of labour, analgesia, steroids, antibiotics, anaesthesia)Delivery date and time, type (natural, caesarean)Episiotomy, laceration (perineal, vaginal), approximate blood loss, amniotic fluid description, umbilical cord descriptionDelivery: neonate data abstracted from medical records (n=854)Sex of neonateAlive/dead status, resuscitation (type of air feed), transfer to neonatal intensive care unitAPGAR scores (1 and 5 min)First and second or third trimesters echography details (when performed)Neonatal clinical evaluation recorded in electronic medical records: malformations, head symmetry, skin colouration, consciousness levelTotal birth length, head circumferenceFeeding during hospitalisation and intent (maternal breast feeding/formula)Length of stay for hospitalisation following delivery (excluding subsequent visits after discharge)Neonatal complications (during hospitalisation postdelivery): neonatology unit care, bradycardia, respiratory problems, hypoglycaemia, hypocalcaemia, hyperbilirubinaemia, polycythaemia, fractures/dislocations, intensive care stay, respiratory therapy, othersPlacental weight

### Medical history (V1, V2, delivery) {#s2b3}

Trained research staff administered standardised questionnaires during study visits to determine participants' medical history. Clinical data regarding any late pregnancy medical updates, perinatal events, delivery details and neonate health parameters at birth were abstracted from electronic health records. Full list of data collected is detailed in [box 1](#bx1){ref-type="boxed-text"}.

### Lifestyle questionnaires (V1, V2) {#s2b4}

Trained research staff administered standardised questionnaires[@R15] at both visits to collect details on diet (food type and frequency), sun exposure, and physical and sedentary activities. Full list of data collected is detailed in [box 1](#bx1){ref-type="boxed-text"}.

### Maternal blood samples (V1, V2) {#s2b5}

At V1, extra blood was collected to obtain plasma and buffy coat 1 h after the 50 g GCT, for storage (for planned DNA extraction). At V2, we collected extra blood samples at fasting, 1 and 2 h over the course of the 75 g OGTT to store plasma and buffy coat, at the same time of clinically indicated blood draws for GDM diagnosis (see [table 4](#BMJOPEN2015010031TB4){ref-type="table"}).

###### 

Biological samples of Gen3G mothers and offspring

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Time point                                                   Sample type (additive)       Maximum number of aliquots   Number of participants that accepted biobanking
  ------------------------------------------------------------ ---------------------------- ---------------------------- -------------------------------------------------
  V1\                                                          Plasma (EDTA)                8                            996
  First trimester after 50 g GCT or non-fasting (2010--2013)                                                             

  Buffy coat (EDTA)                                            1                            962                          

  V2\                                                          Plasma T0---fasting (EDTA)   8                            843
  Second trimester during 75 g OGTT (2010--2013)                                                                         

  Plasma T1 h (EDTA)                                           8                                                         

  Plasma at T2 h (EDTA)                                        8                                                         

  Buffy coat T0 (EDTA)                                         1                            821                          

  Buffy coat T2 h (EDTA)                                       1                                                         

  Delivery (2010--2014)                                        Plasma (EDTA)                16                           662

  Serum (SST)                                                  4                            552                          

  Whole cord blood (NaF, EDTA)                                 4                            403                          

  Buffy coat (EDTA)                                            3                            640                          

  RNA PAXgene\*                                                --                           597                          

  Placenta, fetal side (RNA Later)                             --                           694                          

  Placenta, maternal side (RNA Later)                          --                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Additives: RNA Later, ammonium sulfate; SST, coagulation activator and serum separator; NaF, fluoride sodium.

Data were compiled and accurate on 12 May 2014.

Biobank: denominised data and samples accessible for projects related to other pregnancy-related conditions.

\*RNA PAXgene additive induces cell lysis, stabilises RNA and reduces RNA degradation and gene transcription. This tube was not aliquoted.

GCT, glucose challenge test; Gen3G, Genetics of Glucose regulation in Gestation and Growth; OGTT, oral glucose tolerance test; T0, samples taken under fast; T1 h, samples taken 1 h after the start of the 75 g OGTT; T2 h, samples taken 2 h after the start of the 75 g OGTT.

### Placenta and cord blood samples {#s2b6}

At delivery, we collected cord blood for serum, plasma, buffy coat, whole blood and RNA (in PAXgene tubes). One cm^3^ of maternal and fetal placenta tissue was collected approximately 5 cm from the cord immediately after observation by the obstetrician. These samples were preserved in RNA Later (Qiagen) as indicated by the manufacturer and kept at −80°C for later RNA extraction (see [table 4](#BMJOPEN2015010031TB4){ref-type="table"}).

Handling of biological specimen {#s2c}
-------------------------------

To inhibit protein degradation, aprotinin (1 µL/mL of blood) was added to each blood sample (V1, V2, cord blood) before centrifugation at 2500*g* for 10 min at 4°C. Plasma, serum, whole blood and buffy coats were aliquoted (300--500 µL/aliquot), wrapped in paraffin paper to avoid evaporation, and stored at −80°C. All participants consented to additional analyses, related to our original research questions, using their own and their offspring samples; most also consented to donate any remaining samples to our anonymised biobank (n=996). Maximum numbers of samples collected per type of sample are listed in [table 4](#BMJOPEN2015010031TB4){ref-type="table"}.

Biomarkers measurement {#s2d}
----------------------

The CHUS biomedical laboratory performed the following biochemical measurements on fresh samples (time points listed in [table 5](#BMJOPEN2015010031TB5){ref-type="table"}): plasma glucose (by the glucose hexokinase method; Roche Diagnostics), fasting total cholesterol, high-density lipoprotein-cholesterol and triglycerides (by colorimetric methods; Johnson & Johnson Clinical Diagnostics), low-density lipoprotein-cholesterol levels (calculated using Friedewald\'s equation), HbA1c (by HPLC; Bio-Rad VARIANT), calcium (by colorimetric assay), parathormone (by electrochemiluminescent assay) and phosphorus (by photometry) as previously described.[@R17] Vitamin D (25OHD~2~ and 25OHD~3~) levels were measured in a biochemistry research laboratory (led by collaborator Dr G Fink) at our institution by liquid--liquid extraction followed by liquid chromatography/electrospray tandem mass spectrometry (Quattro micro mass spectrometer; Waters).[@R18] The sum of 25OHD~2~ and 25OHD~3~ levels was considered total plasma 25OHD levels. Minimum detectable concentration (MDC) was 1.25 nmol/L for 25OHD~2~ and 6.25 nmol/L for 25OHD~3~. Intra-assay and interassay CVs were, respectively, 7.4% and 4.1% for 25OHD~2~ and 4.7% and 2.9% for 25OHD~3~.

###### 

Number of clinical and biochemical measures available at each Gen3G research visit

  ------------------------------------------------------------------------------------------------------------------------------------
                                            V1\                         V2\                               Delivery\
                                            5--16 weeks of gestation\   24--28 weeks of gestation\        29--42 weeks of gestation\
                                            Maximum N=1024              Maximum N=898                     Maximum N=854
  ----------------------------------------- --------------------------- --------------------------------- ----------------------------
  Anthropometric measures and vital signs                                                                 

   Pregestational weight                    1024\*                      --                                --

   Height                                   1024                        --                                --

   Weight                                   1024                        882                               854\*

   Bioimpedance                             1017                        865                               --

   Waist circumference                      1001                        --                                --

   Blood pressure                           1022                        880                               --

   Birth weight                             --                          --                                854\*

   Neonate skinfold thickness               --                          --                                265

  Biochemical measures                                                                                    

   Insulin, C peptide, leptin, TNFα         814                         ∼810 per time point during OGTT   658 in cord blood

   Total adiponectin                        479                         851                               645 in cord blood

   Vitamin D (25OHD)                        797                         --                                661 in cord blood

   Plasma glucose                           970                         ∼860 per time point during OGTT   665 in cord blood

   Calcium                                  1017                        810                               --

   Phosphate                                1015                        809                               --

   Parathyroid hormone                      997                         807                               --

   Total cholesterol                        --                          867                               --

   Triglycerides                            --                          867                               --

   HDL-cholesterol                          --                          838                               --

   LDL-cholesterol                          --                          832                               --

   Apo A                                    --                          863                               --

   Apo B                                    997                         863                               --

   HbA1c                                    1015                        865                               --

   Cord blood pO~2~                         --                          --                                812\*

   Cord blood pCO~2~                        --                          --                                817\*

   Cord blood HCO~3~                        --                          --                                817\*

   Cord blood pH                            --                          --                                819\*
  ------------------------------------------------------------------------------------------------------------------------------------

\*Pregestational weight was self-reported. Other starred variables were extracted from electronic hospital records.

Apo A, apolipoprotein A; Apo B, apolipoprotein B; Gen3G, Genetics of Glucose regulation in Gestation and Growth; HbA1c, glycated haemoglobin; HCO~3~, bicarbonate concentration; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; pCO~2~, partial pressure of carbon dioxide; pH, acidity; pO~2~, partial pressure of oxygen; TNF, tumour necrosis factor.

We performed the following biomarker measurements in our common endocrinology research laboratory (see [table 5](#BMJOPEN2015010031TB5){ref-type="table"} for timing and number of samples analysed to date): Cord blood glucose was measured by the glucose hexokinase method (Roche Diagnostics). MDC was 2.5 mM. Intra-assay and interassay CVs were 0.19% and 1.84%.Total adiponectin levels were measured by radioimmunoassay (EMD Millipore). MDC was 0.78 ng/mL. Intra-assay and inter-assay CVs were both \<10%.Insulin, leptin, C peptide and tumour necrosis factor (TNF) α concentrations were measured using a multiplexed particle-based flow cytometric assay (Human Milliplex map kits, EMD Millipore). MDC and lowest curve standard were, respectively, 87 and 45.7 pg/mL for insulin, 41 and 45.7 pg/mL for leptin, 9.5 and 22.9 pg/mL for C peptide, and 0.30 and 0.90 pg/mL for TNFα. Intra-assay and inter-assay CVs were, respectively, \<10% and \<15% for all analytes.

Plasma glucose and insulin values, either under fast or during the 75 g OGTT, were used to calculate the homoeostasis model of assessment of IR (HOMA-IR) as well as dynamic indices of insulin sensitivity and secretion: the Matsuda index (validated in pregnancy[@R19]), the total area under the curve of insulin divided by the total area under the curve of glucose (AUC~insulin/glucose~), and insulin secretion-sensitivity index (ISSI)-2 according to published methods.[@R11] [@R19]

Power calculation {#s3}
=================

Gen3G was planned to recruit over 1000 pregnant women to have adequate power to investigate biomarkers associated with risk of developing GDM and related to impaired glucose regulation in pregnancy. For example, we calculated that we would have 85% power to detect an OR=1.32 increased risk of GDM for each 1 µg/mL reduction of adiponectin (two-sided α 0.05). For genetic analyses, we based our power calculation on candidate genes that were previously shown to influence glycaemic traits in non-pregnant populations: depending on the region and number of single nucleotide polymorphisms tested, we estimated that we would have 80% power to explain between 1.0% and 1.8% of variance of glycaemic-related traits (using continuous measures). We were well aware that we did not have the sample size to conduct genome-wide analyses, but that our sample size and richness of phenotypes would allow us to contribute data to meta-analyses involving multiple cohorts.

Findings to date {#s4}
================

Gen3G completed its recruitment in June 2013 and its follow-up until last delivery in February 2014. Accordingly, major published findings at the time of publication of this manuscript are summarised below.

Evaluating adiponectin and the risk of developing GDM {#s4a}
-----------------------------------------------------

We investigated the role of adiponectin in glucose regulation during pregnancy and the risk of developing GDM[@R22] as defined by IADPSG criteria. We demonstrated that women who developed GDM had lower first trimester adiponectin levels (9.67±3.84 vs 11.92±4.59 µg/mL; p=0.004) when compared with women who remained normoglycaemic. Lower adiponectin levels were associated with a higher risk of developing GDM (OR=1.14 (95% CI 1.04 to 1.25) per 1 µg/mL decrease in adiponectin levels; crude p=0.004) independent of adiposity (BMI, BFP or WC) and glycaemic regulation (HbA1c or glycaemia post-50 g GCT) at first trimester (OR=1.12 (95% CI 1.02 to 1.23); p=0.02 in fully adjusted models). Lower adiponectin levels at first and second trimesters were also associated with higher second trimester IR represented by HOMA-IR (both: r=−0.22, p\<0.0001) and Matsuda index (respectively, r=0.28 and r=0.29, p\<0.0001 for both), independent of age and BMI.

Understanding the role of TNFα in glucose regulation and IR in pregnancy {#s4b}
------------------------------------------------------------------------

The role of TNFα in pregnancy-related IR has been examined[@R20] [@R23] but studies reported conflicting findings. We investigated the association between TNFα levels at first and second trimesters and IR in 756 women from Gen3G, taking into account confounding factors such as adiposity and other IR biomarkers. Our results show that higher maternal circulating TNFα levels were associated with higher IR as assessed by various indices (HOMA-IR: r=0.37, Matsuda: r=−0.30; p\<0.0001 for both), independently from age, BMI, triglycerides and adiponectin levels.[@R26] Interestingly, we detailed for the first time the dynamic response of circulating TNFα over the course of a 75 g OGTT in pregnant women. This study shows that at second trimester, TNFα levels dynamics varied differently in women categorised with elevated IR compared with women categorised with the lowest IR.

Assessing circulating vitamin D as a predictor of GDM {#s4c}
-----------------------------------------------------

Among other biomarkers of interest, we investigated maternal vitamin D circulating levels at first trimester in relation with glycaemic regulation at second trimester and the risk of developing GDM. We demonstrated that lower first trimester 25OHD levels were associated with higher risk of developing GDM (OR=1.48 per SD decrease in 25OHD levels; p=0.04) within model adjusted for vitamin D-related confounding factors (such as season of sampling, parathormone levels and a vitamin D lifestyle score that included dietary intake and sunlight exposure) and known GDM risk factors (history of GDM or macrosomic newborn, maternal age, familial history of diabetes, ethnic background, parity and WC).[@R27] Lower first trimester 25OHD levels were also associated with a higher index of IR (HOMA-IR; r=−0.08; p=0.03), a lower Matsuda index (r=0.13; p=0.001) and a lower ISSI-2 (r=0.08; p=0.04) assessed at second trimester.

Strengths and limitations {#s5}
=========================

One of the Gen3G cohort\'s main strength is its prospective design from early pregnancy to delivery. The large sample size and population-based design allow inferring results to the general population of pregnant women in our region, but also to other populations who are mainly of European descent. We conducted detailed and standardised anthropometric measurements and lifestyle questionnaires that allow us to take into account most known potential confounders to glycaemic regulation impairments. We collected maternal blood samples at multiple time points of pregnancy and we successfully obtained cord blood and/or placenta in about 80% of deliveries. Placenta material in particular is a feature that few mother--child cohorts have. This opens the possibility of investigating epigenetics and gene expression (RNA and/or protein) specific to the role of placenta in health and diseases related to pregnancy. Gen3G sample size and collection of DNA on both mother and offspring also allow sufficient power to perform genetic association studies, for candidate genes approaches if considering Gen3G sample size alone, or as a decent additional cohort to contribute to meta-analyses. Integration of both genetics and epigenetics in our study is particularly attractive for questions related to the developmental origin of health and disease field. Of note, follow-up of mothers and children at 3 and 5 years old is ongoing. Visits include questionnaires, measures of anthropometry and collection of biological samples for genetic analyses and measures of biomarkers related to adiposity and glycaemia in both mothers and children. One other major strength resides in the vision the investigators invested in this cohort. Biological samples were collected, aliquoted and stored for future research questions and hypotheses related either to glycaemic regulation or other disorders of pregnancy (biobank, maximum n=996).

Limitations include the absence of fasting blood samples at first trimester, which would have allowed calculation of the IR index HOMA-IR early in pregnancy. Moreover, some biomarkers measured at first trimester are more sensitive to fasting status (eg, leptin and TNFα); not being able to measure their fasted levels at first trimester might have influenced our interpretation of change over the course of pregnancy. Fasting samples would also have been particularly useful for measurement of potential biomarkers that are highly sensitive to food intake, such as lipid, carbohydrates and amino acids metabolites that are now part of the upcoming field of metabolomics; however, emerging literature suggests that postglucose load metabolomics might be highly informative for investigations of weight and glycaemic-related traits.[@R28] In addition, as the Eastern Townships population is mostly of European descent, our homogenous cohort population prevents generalisation of our results to populations with other ethnic background (Asian, Hispanic, Indigenous, African), who usually have a higher risk of GDM compared with women of European descent.

In hindsight, our data would have been enriched by adding a research visit during third trimester, for which we relied on medical records to collect end-of-pregnancy data that are not as reliable as standardised research assessments. Similarly, collection of paternal data and samples would have increased our ability to take into account familial factors and investigate parent-of-origin effect in our genetic studies. Also, emerging interests in microbiota and its relation to metabolism in pregnancy and offspring also lead us to believe that collecting stool, urine and amniotic fluid samples would have been of great value in our cohort. However, our choices of balancing ease of recruitment, participants' burden and additional procedures, were to limit attrition---which was consequently relatively small compared with similar studies.[@R31] [@R32]

Future plans {#s5a}
------------

We are now in the phase of prospective follow-up of mothers and offspring 3 and 5 years postdelivery to investigate the consequences of maternal dysglycaemia during pregnancy on offspring adiposity and metabolic profile. We are seeking funding to enrich phenotypic characterisation and additional samples collection for epigenetic and biomarkers studies. We hope to continue to follow-up Gen3G participants over many years to come, if we have adequate funding and support.

Collaboration {#s6}
=============

Collaboration propositions are welcome, either in the form of accessing questionnaire-based data and/or biological samples. Investigators interested in GDM or other disorders of pregnancy can propose their ideas to have access to data/samples stored in our biobank. To discuss collaboration possibilities, investigators are invited to contact M-FH and PP (mhivert\@partners.org; patrice.perron\@usherbrooke.ca).
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